Short description
Dynavax Technologies is a biopharmaceutical company discovering and developing novel products to prevent and treat infectious diseases.
Description
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Berkeley, California, United States, North America
Founded on
January 1, 1996
Exited on
February 19, 2004
Went public on
February 19, 2004
Stock symbol
DVAX
Non-profit?
No
Acquired?
No
Employees count
501-1000
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noaccessforu, Absolutely Noaccess, Noway Youcantaccess, Cannot Access, Absolutely Noaccess, Uh Ohhhh, Absolutely Noaccess, No Way, Noaccessforu, Blurry Noaccess, Uh Ohhhh, Noaccess, Absolutely Noaccess, Nopepepe, No Way, Noway Youcantaccess, Noaccessforu, Absolutely Noaccess, Nopepepe
Sign in for full access
Founders
Dennis Carson